Back to QDEL
Quidel to Present at Upcoming Conferences

SAN DIEGO, CA -- (Marketwire) -- 05/31/12 -- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today that it will present at the following upcoming conferences:

  • The Goldman Sachs 33rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California on Tuesday, June 5, 2012 at 3:20 p.m. Pacific Time.

  • The William Blair 32nd Annual Growth Stock Conference at the Four Seasons hotel in Chicago, Illinois on Tuesday, June 12, 2012 at 7:30 a.m. Central Time.

Douglas Bryant, president and chief executive officer, will present on the specified days with a question and answer session scheduled immediately following the presentations. During the presentations, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed.

A live webcast and audio archive of the presentations will be available via the Investor Relations section of the company's Web site at www.quidel.com. Participants should allow approximately five to ten minutes prior to each presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of each webcast will also be available on the company's Web site for 14 days.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue®, D3® Direct Detection and Thyretain™ leading brand names, as well as under the new Sofia® brand, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.

Back to QDEL
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki